After the survey, all patients desired to continue with iPCSK9.

**Conclusion** After 6–12 weeks of iPCSK9 treatment, all patients reduced LDL level except 1 who was non-adherent. The LDL reduction ranged between 54%–71% and all patients on evolocumab achieved a LDL <70 mg/dL.

The tolerability was excellent and only mild adverse events in about 8% of patients were experienced.

A high acceptance of both alirocumab and evolocumab was reported by all patients who would continue with iPCSK9 treatment.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

---

**4CPS-026 ADHERENCE AND EFFECTIVENESS OF PCSK9 INHIBITORS IN ROUTINE CLINICAL PRACTICE**

P Gabaldón García*, C Sobrino Jiménez, F Moreno Ramos, L González del Valle, C Jiménez Vicente, A Herrero Ambrosio, Hospital Universitario La Paz, Pharmacy, Madrid, Spain

10.1136/ehjpharm-2019-ehahpconf.175

**Background** Alirocumab and evolocumab are monoclonal antibodies that belong to a new class of cholesterol-lowering drugs by inhibiting the proprotein convertase subtilisin/kexin type-9 (PCSK9) enzyme.

**Purpose** The main objective of this study was to evaluate the adherence to alirocumab and evolocumab therapies and its relation to drug effectiveness.

**Material and methods** Observational, descriptive and retrospective study conducted in a tertiary hospital. All patients that initiated treatment with alirocumab and evolocumab from October 2016 to February 2018 were included.

Data sources were patients’ electronic medical records and outpatients’ electronic prescription and dispensation programme. Main variables collected were: gender, age, indication, prescriber’s medical departments and low-density lipoprotein (LDL-C).

Adherence was calculated indirectly by consulting dispensing data in the outpatient prescription tool.

Effectiveness was defined as the percentage decrease in LDL-C from baseline to week 24.

**Results** Forty patients were included: 22 men (55%) and 18 women (45%), with median age 57 years (19–83). Nine patients (22.5%) had heterozygous primary hypercholesterolemia, seven (17.5%) heterozygous primary hypercholesterolemia and severe cardiovascular disease, 11 (27.5%) severe cardiovascular disease, 10 (25%) severe cardiovascular disease and statin intolerance, and three (7.5%) statin intolerance. Alirocumab was prescribed in 19 patients (47.5%) and evolocumab in 21 (52.5%).

Mean adherence index was 1.03 (SD 0.13). Mean basal LDL-C and LDL-C after 24 weeks were 125, 42 mg/dl (SD 43.34) and 61, 22 mg/dl (SD 44.17), respectively. The percentage decrease in LDL-C from baseline to week 24 was 43%, 31% in the alirocumab group and 54% in the evolocumab group. The adherence index in both groups was similar.

Twenty-eight patients (70%) had a percentage decrease in LDL-C >40% with an adherence index of 1.04 (SD 0.12), while 12 patients (30%) had a percentage decrease in LDL-C <40% with an adherence index of 1.01 (SD 0.15).

**Conclusion**

- Patients under PCSK9-inhibitors treatment are strong adherents to these therapies.
- Effectiveness of PCSK9-inhibitors in routine clinical practice has been proven with data comparable to randomised clinical trials. Apparently, evolocumab shows better effectiveness than alirocumab.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**


No conflict of interest.
REAL-WORLD EFFECTIVENESS OF EVOLOCUMAB AND ALIROCUMAB AT 12 MONTHS OF TREATMENT

1M Gomez Zamora*, 1P Rovira Torres, 2A Jimenez Portilla, 1M Ortiz, 1A Gomez Lobon, 1MM Santandreu Estelich, 1E Rodriguez Campos, 1O Delgado Sanchez, 1R Urgeles Parelleta. 1Hospital Universitario Son Espases, Pharmacy, Palma de Mallorca, Spain; 2Hospital Universitario Son Espases, Endocrinology, Palma de Mallorca, Spain

Background Alirocumb and Evolocumab are proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-I) that have been authorised by the Autonomous Health Service under the following conditions: uncontrolled familial hypercholesterolemia (FH) with low-density lipoprotein (LDL-C) >130 mg/dL, uncontrolled stable atherosclerotic cardiovascular disease (ASCVD) with LDL-C >130 mg/dL or unstable ASCVD with LDL-C >100 mg/dL in combination with a statin and ezetimibe at maximum tolerated doses.

Purpose We aim is to analyse the effectiveness of PCSK9-I in patients treated at a tertiary care hospital

Material and methods Retrospective study of all patients treated with PCSK9-I from April 2016 to June 2017 and follow-up at 12 months of treatment. The variable of effectiveness analysed was the percentage of reduction in LDL-C.

Results Thirty-eight patients were included, median age of 56 years (35–80), 53% women. In 19 (50.0%) cases, PCSK9-I were indicated for ASCVD, in 15 (39.5%) for FH and in four (10.5%) for both indications: 15 (39.5%) patients were intolerant to statins and seven (18.4%) to ezetimibe. The mean level of initial LDL-C was 180.5±49.4 mg/dL. PCSK9-I were prescribed in combination with statins in 25 (65.8%) patients and ezetimibe 24 (63.2%). Evolocumab was indicated in 27 (71.1%) cases and alirocumab in 11 (28.9%). The recommended target for LDL-C was 100 mg/dL for 14 patients and 70 mg/dL for 24. After 12 months, median 53 weeks (42–76), data were collected from 25 (65.8%) patients, in 11 cases (28.9%) the blood test was not done and two (5.3%) discontinued treatment. The mean LDL-C was 84.6±43.8 mg/dL, with a relative percentage reduction of 50.8%±34.8%. There was no significant difference in effectiveness between evolocumab and alirocumab (−55.2% vs −40.8%, p=0.408). The therapeutic goal was achieved in 15 (60%) patients.

Conclusion PCSK9-I showed similar LDL-C reductions to those described in clinical trials (50%–70%), although only 60% of patients achieved the recommended goal after 1 year of treatment.

REFERENCES AND/OR ACKNOWLEDGEMENTS


No conflict of interest.